Overview of restricted ingredients
Japan does not have a single "supplement ingredient" framework equivalent to the US Dietary Supplement Health and Education Act (DSHEA). Instead, supplement ingredients are evaluated under the Food Sanitation Act, the PMD Act, and MHLW guidance documents. This means ingredient restrictions apply at multiple regulatory levels.
The key risk categories are: ingredients classified as pharmaceuticals (prohibited in food products), ingredients with quantity restrictions in food products, and ingredients subject to ongoing MHLW review due to safety concerns.
Stimulants and caffeine
| Ingredient | Japan Status | Limits / Notes |
|---|---|---|
| Caffeine (synthetic) | Restricted | Max 150mg per serving in beverages; no limit in food but high-dose products face scrutiny |
| Ephedrine alkaloids | Prohibited | Classified as pharmaceutical; prohibited in food supplements |
| DMAA (methylhexanamine) | Prohibited | No approved food use; classified as pharmaceutical stimulant |
| Synephrine (bitter orange) | Under review | Not explicitly prohibited but high-dose products face classification risk |
| Guarana extract | Permitted | Permitted as natural caffeine source; quantity limits apply in beverages |
Products marketed as "pre-workout," "fat burner," or "energy" supplements require particularly careful ingredient review for the Japan market. Many standard Western formulations contain stimulant compounds that trigger pharmaceutical classification in Japan.
Botanical extracts under review
Several botanical extracts widely used in Western supplement markets are subject to MHLW review or restriction in Japan:
- Kava (Piper methysticum): MHLW has issued warnings about liver toxicity; high-dose products face significant classification risk
- Valerian: Permitted at low doses; quasi-drug classification risk at therapeutic doses
- St. John's Wort: MHLW has issued safety advisories; pharmaceutical classification risk for mood-related claims
- Ginkgo biloba: Generally permitted; specific extract concentrations may trigger review
- Coleus forskohlii (forskolin): Limited approved use; weight management claims create pharmaceutical risk
For any product containing botanical extracts, verify each extract's approved status in Japan before import. The approved use may be narrower than in your home market.
Cannabinoids in Japan
Japan has strict controls on cannabis-derived compounds. As of 2026, CBD (cannabidiol) derived from hemp is in a complex regulatory position:
Japan amended its Cannabis Control Act in 2023, with reforms taking effect in phases through 2024-2025. Under the amended framework, CBD products derived from hemp (with THC within legal limits) may be legally imported, but the regulatory pathway requires specific compliance steps.
Japan Market Gateway has direct experience with cannabinoid product imports through our CBD Logistics operation. If you are looking to import CBD or hemp-derived products into Japan, please contact us directly — this category requires specialized compliance guidance that goes beyond a standard Feasibility Report.
How to check your formula
The most reliable approach to ingredient compliance verification is a systematic three-step review:
- MHLW additive database check: Verify every ingredient in your formula against MHLW's current approved food additive list
- PMD Act check: Review whether any ingredient is listed as a pharmaceutical ingredient under Japan's drug monographs
- MHLW guidance review: Check for any recent MHLW guidance documents or safety advisories for your specific ingredients
For complex formulas or products with multiple active ingredients, a JMG Feasibility Report provides a complete ingredient-level compliance assessment specific to the Japan market.
Ready to move from
research to action?
Get a fast, authority-verified answer on whether your specific product can enter Japan — and exactly what compliance steps are required.
One-time · email delivery · 10–15 business days